nivolumab,ipilimumab
bms
['check,mate,9la', 'lcsm,(-blcsm)', '9la']
lba9023; checkmate 9la; 4y update. landmark tail about 20% regardless of pdl1 level and histology. don t be scared of tx discontinuation those pts have a 41% 4y tail. patients do well. #asco23 #lcsm 
Consultant Medical Oncologist, UK. Views are hypothesis generating discourse. Post COVID dabbling in garden.